Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    European urology oncology · 2025
    RKRohit Kumar Jain
    PMID: 40307092DOIeCommonsFirst author1 citations
  2. 2
    Clinical genitourinary cancer · 2021
    RKRohit Kumar Jain
    PMID: 34011489PMCID: PMC8526625DOIFirst author17 citations

Publications

79 publications

Clinical research

4 studies

Active

3 studies
  • PI
    FORAGER-1: A Phase 1, Open-Label, Multicenter Study of Vepugratinib (LY3866288; LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer and Muscle Invasive Bladder Cancer With FGFR3 Alterations
    PHASE1 · Eli Lilly and Company · OPEN TO ACCRUAL (as of 2026)
    Urinary Bladder Neoplasms; Neoplasm Metastasis; Ureteral Neoplasms
    NCT05614739
  • PI
    Single Arm Phase II Study of Bladder Preservation With Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (BRIGHT)
    PHASE2 · SWOG Cancer Research Network · OPEN TO ACCRUAL (as of 2026)
    Muscle Invasive Bladder Urothelial Carcinoma; Stage II Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8
    NCT07061964
  • PI
    Phase 1 Trial of CA-4948 in Combination With Pembrolizumab to Overcome Resistance to PD-1/PD-L1 Blockade in Metastatic Urothelial Cancer
    PHASE1 · National Cancer Institute · OPEN TO ACCRUAL (as of 2025)
    Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma
    NCT06439836
Completed & closed trials (1)
  • PI
    Phase Ib Trial of Erdafitinib Combined With Enfortumab Vedotin Following Prior Therapies for Metastatic Urothelial Carcinoma With FGFR2/3 Genetic Alterations
    PHASE1 · National Cancer Institute · CLOSED TO ACCRUAL (as of 2025)
    Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis Urothelial Carcinoma; Locally Advanced Ureter Urothelial Carcinoma; Locally Advanced Urethral Urothelial Carcinoma; Locally Advanced Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Recurrent Bladder Urothelial Carcinoma; Recurrent Renal Pelvis Urothelial Carcinoma; Recurrent Ureter Urothelial Carcinoma; Recurrent Urethral Urothelial Carcinoma; Recurrent Urothelial Carcinoma; Stage IIIB Bladder Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Renal Pelvis Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8
    NCT04963153

External relationships

Advisory/Scientific Board Member

AstraZeneca, PLC · Eli Lilly and Company · Exelixis, Inc. · Natera, Inc. · Novartis Pharmaceuticals Corporation